reserpine has been researched along with Disease Exacerbation in 7 studies
Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.
reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.
| Excerpt | Relevance | Reference |
|---|---|---|
| " After 4 weeks of DOCA-salt hypertension, rats were either killed (n = 6), or treated with a non-hypotensive dose of spironolactone (n = 7) or triple therapy (hydrochlorothiazide, reserpine and hydralazine, n = 8) to normalize blood pressure or with vehicle (n = 19) for two further weeks." | 3.74 | Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension. ( Cordasic, N; Hartner, A; Hilgers, KF; Klanke, B; Schmieder, RE; Veelken, R, 2008) |
| " The aim of this study was to compare the effects of an equivalent reduction in blood pressure produced by the angiotensin-converting enzyme (ACE) inhibitor spirapril (SPI) and an antihypertensive triple drug combination of hydralazine, reserpine and hydrochlorothiazide (HRH) on kidney function, proteinuria and renal structure in hypertensive diabetic rats." | 3.70 | Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats. ( Armini, L; Bardelli, M; Calci, M; Campanacci, L; Candido, R; Carretta, R; Fabris, B; Fazio, M; Fischetti, F, 1999) |
| " Here, we evaluated whether chronic administration of an NO donor, molsidomine, controlled systemic blood pressure and renal disease progression and prolonged survival in rats with renal mass reduction (RMR)." | 1.30 | Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. ( Benedetti, G; Benigni, A; Bruzzi, I; Corna, D; Noris, M; Remuzzi, G; Todeschini, M; Zoja, C, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Campêlo, CLC | 1 |
| Santos, JR | 1 |
| Silva, AF | 1 |
| Dierschnabel, AL | 1 |
| Pontes, A | 1 |
| Cavalcante, JS | 1 |
| Ribeiro, AM | 1 |
| Silva, RH | 1 |
| El-Sayeh, HG | 1 |
| Rathbone, J | 1 |
| Soares-Weiser, K | 1 |
| Bergman, H | 1 |
| Ortiz, A | 1 |
| Gui, J | 1 |
| Zahedi, F | 1 |
| Yu, P | 1 |
| Cho, C | 1 |
| Bhattacharya, S | 1 |
| Carbone, CJ | 1 |
| Yu, Q | 1 |
| Katlinski, KV | 1 |
| Katlinskaya, YV | 1 |
| Handa, S | 1 |
| Haas, V | 1 |
| Volk, SW | 1 |
| Brice, AK | 1 |
| Wals, K | 1 |
| Matheson, NJ | 1 |
| Antrobus, R | 1 |
| Ludwig, S | 1 |
| Whiteside, TL | 1 |
| Sander, C | 1 |
| Tarhini, AA | 1 |
| Kirkwood, JM | 1 |
| Lehner, PJ | 1 |
| Guo, W | 1 |
| Rui, H | 1 |
| Minn, AJ | 1 |
| Koumenis, C | 1 |
| Diehl, JA | 1 |
| Fuchs, SY | 1 |
| Klanke, B | 1 |
| Cordasic, N | 1 |
| Hartner, A | 1 |
| Schmieder, RE | 1 |
| Veelken, R | 1 |
| Hilgers, KF | 1 |
| Villar-Cheda, B | 1 |
| Rodríguez-Pallares, J | 1 |
| Valenzuela, R | 1 |
| Muñoz, A | 1 |
| Guerra, MJ | 1 |
| Baltatu, OC | 1 |
| Labandeira-Garcia, JL | 1 |
| Benigni, A | 1 |
| Zoja, C | 1 |
| Noris, M | 1 |
| Corna, D | 1 |
| Benedetti, G | 1 |
| Bruzzi, I | 1 |
| Todeschini, M | 1 |
| Remuzzi, G | 1 |
| Fabris, B | 1 |
| Candido, R | 1 |
| Armini, L | 1 |
| Fischetti, F | 1 |
| Calci, M | 1 |
| Bardelli, M | 1 |
| Fazio, M | 1 |
| Campanacci, L | 1 |
| Carretta, R | 1 |
1 review available for reserpine and Disease Exacerbation
| Article | Year |
|---|---|
Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia.
Topics: Adrenergic Uptake Inhibitors; Anti-Dyskinesia Agents; Antipsychotic Agents; Celiprolol; Disease Prog | 2018 |
6 other studies available for reserpine and Disease Exacerbation
| Article | Year |
|---|---|
Exposure to an enriched environment facilitates motor recovery and prevents short-term memory impairment and reduction of striatal BDNF in a progressive pharmacological model of parkinsonism in mice.
Topics: Animals; Avoidance Learning; Brain-Derived Neurotrophic Factor; Catalepsy; Corpus Striatum; Disease | 2017 |
An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles.
Topics: Animals; Cell Line, Tumor; Disease Progression; Extracellular Vesicles; Gene Expression Regulation, | 2019 |
Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Desoxycorticosterone; Disease Models, Animal; Dise | 2008 |
Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: implications for progression of Parkinson's disease.
Topics: Adrenergic Uptake Inhibitors; Angiotensin II; Animals; Corpus Striatum; Disease Progression; Dopamin | 2010 |
Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Body Weight; Creatinine; Disease | 1999 |
Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Diabetic | 1999 |